News & Events zu Rockwell Medical Inc (RMTI)RMTIRockwell Medical Inc

Rockwell Medical Withdraws 2026 Financial Guidance

Rockwell Medical is withdrawing its previously issued 2026 guidance for Net Sales, Gross Margin, Adjusted EBITDA and Operating Cash Flow due to projected expenses related to expected transaction-related and financing-related expenses associated with the proposed Vantive acquisition. Adjusted EBITDA is a non-GAAP financial measure; the Company's previously issued reconciliation and related disclosures remain applicable to the historical periods presented.

Rockwell Medical Acquires Vantive Assets for $125 Million

Rockwell Medical announced that it has entered into an Equity and Asset Purchase Agreement with Vantive Limited. Subject to the terms of the Agreement, Rockwell Medical will acquire Vantive's hemodialysis concentrates, HD machines including AK-98, water treatment systems, and related consumables and technical services business. In addition, subject to the terms and conditions of the Agreement, Rockwell Medical will acquire Vantive's state-of-the art one million square foot manufacturing campus in Medolla, Italy, an integral municipality within the Mirandola Biomedical District, the third largest medtech region in the world. The Medolla campus currently manufactures dry concentrate cartridges, HD machines, related parts and consumables, and water treatment systems that support the broader HD product portfolio. Under the terms of the Agreement, the aggregate base purchase price is $125 million, subject to customary adjustments, and will be financed through two $50 million term loans from Vantive plus a $25 million convertible note issued to Vantive. The convertible note will have an initial conversion price equal to a 100% premium to the 15-day Volume-Weighted Average Price of Rockwell Medical's common stock determined as provided in the definitive transaction documents. Vantive may also receive up to $45 million of additional contingent consideration based on specified revenue and EBITDA milestones. The foregoing summary is qualified in its entirety by the Company's Form 8-K disclosing the transaction. The transaction is expected to close mid-2027, subject to receipt of required regulatory approvals and satisfaction or waiver of the other closing conditions set forth in the Agreement. There can be no assurance that the transaction will be completed on the anticipated timeline or at all. Rockwell Medical will determine the accounting treatment of this transaction in accordance with U.S. Generally Accepted Accounting Principles ("GAAP"). If completed, the transaction will be reflected in the Company's financial results following the closing.

Company Reports Q2 Revenue of $17.8M

Reports Q2 revenue $17.8M vs. $16.1M last year. "The momentum in our business continues to build. Our second quarter results reflect the outcome of the actions we have taken to strengthen our commercial position, improve operational efficiency, and enhance profitability," said CEO Mark Strobeck. "We are a fundamentally stronger company today, with a growing customer base, improving margins, a solid cash position, and a clear path toward achieving our 2026 guidance. As we enter the second half of the year, we remain focused on executing our growth strategy, expanding profitability, generating positive cash flow, and delivering long-term value for shareholders."